Prosight Management, LP Nuvation Bio Inc. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $2.63 Million - $7.15 Million	-1,800,000 Reduced 87.8%	250,000 $910,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $960,000 - $1.53 Million	1,000,000 Added 95.24%	2,050,000 $3.1 Million
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $63,000 - $105,000	-50,000 Reduced 4.55%	1,050,000 $1.41 Million
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $1.72 Million - $2.02 Million	1,100,000 New	1,100,000 $1.98 Million
Q3 2021 Nov 12, 2021	SELL	$7.78 - $10.0 $713,379 - $916,940	-91,694 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $845,418 - $1.33 Million	91,694 New	91,694 $854,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.